|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's range||10.65 - 12.18|
|52-week range||3.84 - 16.65|
|Beta (5Y monthly)||2.20|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Good morning, everyone, and welcome to the G1 conference call to discuss our second quarter '22 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the second quarter of '22, including an update on our clinical programs and our commercial progress in that period with Cosela, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide containing regimen or topotecan containing regimen for extensive-stage small cell lung cancer or ES-SCLC.
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?